GBI Research’s latest report, “”Evolving Market Access Strategies – Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets”” assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=561075
Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.
– What strategies can pharmaceutical companies implement in order to overcome these challenges?
HEOR plays a critical part in market access
– How does HEOR help internal decision making?
– How can a systemic value development plan (SVDP) optimize HEOR?
– How do cost-effectiveness analyses play a role in the commercial success of a new product?
HTA has gained importance in reimbursement decisions
– What are the different concepts and general processes involved in HTA?
– What are the key benefits of HTA?
Pricing and reimbursement are the key elements of market access
– What are the most important factors considered in pricing decisions?
– What are the pricing and reimbursement policies in the US, Canada, UK, Germany, France, Italy, Spain and Japan?
Table of Content
Health Economic and Outcomes Research (HEOR)
A Systemic Value Development Plan for HEOR
Types of Economic Evaluations
Overview of Cost-Effectiveness Analysis
Quality-Adjusted Life Year in HEOR
Pharmacoeconomic Modelling Methods
Health Technology Assessment (HTA) in Market Access
Key Benefits of HTA
Process and Dimensions of HTA
Principle HTA Regulatory Agencies
Risk Sharing Agreements When Limited Evidence is Available for HTA
Pricing and Reimbursement
Factors Affecting Pricing Decision
Pricing of a New Drug
Pharmaceutical Pricing Policies in the US
Impact Of Affordable Care Act on Market Access
Pharmaceutical Pricing and Reimbursement Policies in Canada
Pharmaceutical Pricing and Reimbursement Policies in Europe (UK, Germany, France, Italy and Spain)
Parallel Trade in Europe
Pharmaceutical Pricing and Reimbursement Policies in Japan
Economic Analysis Alongside Clinical Trials
Harmonization of Drug Approval and Marketing for Effective Market Access
Key Challenges for Achieving Optimum Market Access
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=561075